Rocco Morelli Named Interim CEO of Recombinetics™, Global Leader in Genetically Engineered Animals
Retrieved on:
Tuesday, January 18, 2022
Health, Genetics, Other Health, General Health, Biotechnology, Veterinary, Board, Genetic engineering, Human, Electrical engineering, Southern Ohio Medical Center, Combat engineer, Loyola University, Growth, Director, Health, CEO, Combat, GE, Mathematics, Leadership, Trustee, Animal, Tissue, Morelli, Vanderbilt University, Marketing, Therapy, Gundersen Health System, Genetics, Miniature pig, Spacelabs Healthcare, Loyola University Chicago, Engineering, Cell, Senior, Xenotransplantation, Management, Finance, Recombinetics, Makana Therapeutics, Recombinetics, MAKANA THERAPEUTICS, RECOMBINETICS
Recombinetics Inc., a global leader in the development, deployment, and commercialization of genetically engineered animals, announced today that Rocco Morelli has been named the companys interim Chief Executive Officer (CEO) effective immediately.
Key Points:
- Recombinetics Inc., a global leader in the development, deployment, and commercialization of genetically engineered animals, announced today that Rocco Morelli has been named the companys interim Chief Executive Officer (CEO) effective immediately.
- Morelli succeeds Mark Platt, who is assuming the role full-time as President and CEO of Makana Therapeutics, a subsidiary of Recombinetics and a leader in the field of xenotransplantation.
- Recombinetics and Makana have expertise and strong intellectual property positions in clinical organ transplantation, genetic engineering, reproductive technology, and xenotransplantation.
- Founded in 2008, Recombinetics is a recognized global leader in the development, deployment, and commercialization of genetically engineered animals.